Evaluation of pharmacokinetic herb-drug interaction of diabecon and losartan by UHPLC-MS/MS.

Autor: Prasanna Kumari Rayala VVS; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India., Shantilal Shinde R; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India., Kumar A; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India., Radhakrishnanand P; Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India. Electronic address: radha.krishnanand@niperguwahati.ac.in.
Jazyk: angličtina
Zdroj: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences [J Chromatogr B Analyt Technol Biomed Life Sci] 2024 Sep 15; Vol. 1245, pp. 124267. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1016/j.jchromb.2024.124267
Abstrakt: The diabecon is an ayurvedic herbal formulation that contains a mixture of herbs traditionally used as antidiabetic which is reported in the ayurvedic pharmacopeia of India and Indian Materia medica. The diabetic population has a common co-morbidity of hypertension for which losartan drug is commonly used for the treatment of hypertension. However, there is a lack of research on the pharmacokinetics interaction between diabecon and losartan. This research aims to investigate the influence of diabecon on the pharmacokinetics of losartan drugs in rats by establishing a highly sensitive ultra-high performance liquid chromatography-tandem triple quadrupole mass spectrometry (UHPLC-MS/MS) method. The method was validated according to the USFDA guidelines and was applied for the pharmacokinetic study. The lowest concentration of losartan detection in rat plasma was found to be 1 ng/mL and the accuracy and precision were within the linear range (1-1500 ng/mL). The results revealed that after 28 days of dosing diabecon, it has altered the pharmacokinetic parameters like area under the curve (AUC 0-t ), drug clearance (Cl/F), and rate of elimination (Ke) of losartan, which may happen due to enzyme induction. Although there was a change in the pharmacokinetic parameters of losartan when administered in the presence of diabecon, it was found to be nonsignificant in rats (p > 0.05). According to the best of our knowledge, this is the first article that discusses the pharmacokinetic herb-drug interaction between diabecon and losartan.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: